The tweet was deleted by the author.
But we saved everything 🙂.
Lexicon Pharmaceuticals announced it will participate in the HCWCO BioConnect Investor Conference this week.
The company’s management team is scheduled to take part in a fireside chat on May 19 at Nasdaq headquarters in New York City, offering insights into its strategic initiatives and engaging with the investor community.
Lexicon is advancing late-stage clinical programs, including the SONATA-HCM Phase 3 trial of its SGLT1/SGLT2 inhibitor for hypertrophic cardiomyopathy. The company also recently presented Phase 2b data at AAN 2026 supporting a 10 mg dose for diabetic peripheral neuropathic pain. These developments come as management prepares to outline strategic initiatives to investors in New York.